Effect of piperazine oestrone sulphate on serum lipids and lipoproteins in menopausal women.
Twenty menopausal women and 2 women with gonadal dysgenesis were treated with piperazine oestrone sulphate 1.5-3 mg dialy on a cyclical basis for a period of 6 months. Fasting serum lipids and lipoprotein esterified fatty acid indices (EFI) were estimated before starting treatment and after 3 and 6 months. There were small falls in serum cholesterol (significant at 3 months) and beta-lipoprotein EFI (significant at 6 months). Serum triglyceride and pre-beta-lipoprotein EFI rose significantly at both 3 and 6 months. Serum total phospholipid levels were reduced (significant at 6 months) with most marked changes in the sphingomyelin fraction. Other parameters were not significantly altered.
D002784:Cholesterol / Q000097:blood; D002979:Climacteric; D004970:Estrone / Q000494:pharmacology* / Q000627:therapeutic use; D005227:Fatty Acids / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008593:Menopause; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood; D014424:Turner Syndrome / Q000188:drug therapy
D005227:Fatty Acids; D005230:Fatty Acids, Nonesterified; D008055:Lipids; D008074:Lipoproteins; D010743:Phospholipids; D010879:Piperazines; D014280:Triglycerides; D004970:Estrone; D002784:Cholesterol